Journal article

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G Hanna, Shankar Siva, Shom Goel, Steven David

BMC CANCER | BMC | Published : 2021


BACKGROUND: The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had improved the outcomes of patients with advanced ER-positive HER2-negative breast cancer. However, the disease often progresses following a period of treatment response. In a subset of patients, disease progression may occur at limited sites, i.e., oligoprogressive disease (OPD). In the past few years, stereotactic radiotherapy (SRT) has emerged as a safe and effective treatment for advanced cancer when delivered to limited metastatic sites. Hence,..

View full abstract


Funding Acknowledgements

The study is sponsored by Peter MacCallum Cancer Centre Foundation. The funding body did not play any roles in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.